Christopher Cannon from the Harvard Clinical Research Institute: ACC Provides Guidance on Non-Statin Therapies
As doctors have more tools to treat patients with high cholesterol the American College of Cardiology released a new consensus statement to give guidance on potential best practices for non-statin therapies like PCSK9 inhibitors.
As doctors have more tools to treat patients with high cholesterol the American College of Cardiology released a new consensus statement to give guidance on potential best practices for non-statin therapies like PCSK9 inhibitors.
Speaking at the 65th Annual Scientific Sessions and Expo in Chicago, Christopher Cannon, MD, from the Harvard Clinical Research Institute said the new document will help doctors to move away from more controversial guidelines released in 2013 and towards a clearer approach to treatment going forward as new treatment methods are developed.
